## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.7% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($757.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Quantbot Technologies LP Has $1.40 Million Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251208T110544 | Bullish | Relevance: 99%
-  Quantbot Technologies LP significantly reduced its stake in McKesson Corporation, selling 65.2% of its shares but still holding 1,906 shares valued at approximately $1.40 million. McKesson has largely positive Wall Street sentiment with a "Moderate Buy" rating and an average price target of $887.69, following an EPS beat and a 10.2% revenue increase year-over-year. The company recently announced a quarterly dividend of $0.82 per share.

**2. McKesson Corporation $MCK Shares Sold by Lombard Odier Asset Management USA Corp**
- Source: MarketBeat | 20251209T133143 | Neutral | Relevance: 98%
-  Lombard Odier Asset Management USA Corp significantly reduced its stake in McKesson Corporation (NYSE:MCK) by 57.8% in the second quarter, selling over 4,200 shares. Despite this, several other institutional investors, including Norges Bank and Nuveen LLC, purchased new stakes or increased their holdings in McKesson during recent quarters. Analysts hold a "Moderate Buy" rating for McKesson with a consensus target price of $892.86.

**3. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Invests $1.87 Million in McKesson Corporation $MCK**
- Source: MarketBeat | 20251209T134343 | Bullish | Relevance: 97%
-  Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna recently acquired a new stake of 2,552 shares, valued at approximately $1.87 million, in McKesson Corporation (NYSE:MCK). This investment is part of a broader trend where institutional investors and hedge funds own 85.07% of McKesson's stock, alongside recent adjustments in holdings by other investment firms. McKesson has also received favorable analyst ratings and recently announced a quarterly dividend, indicating ongoing investor confidence and strong financial performance.

**4. California Public Employees Retirement System Sells 96,231 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251207T090817 | Somewhat-Bullish | Relevance: 95%
-  California Public Employees Retirement System (CalPERS) reduced its stake in McKesson Corporation (NYSE:MCK) by 15.8%, selling 96,231 shares but retaining 512,057 shares valued at $375.2 million. This comes as McKesson exceeded quarterly EPS estimates, and analysts have a "Moderate Buy" consensus rating with a target price around $887.69. The company also declared a quarterly dividend of $0.82 per share.

**5. 1 Healthcare Stock with Impressive Fundamentals and 2 We Brush Off**
- Source: Markets Financial Content | 20251208T040915 | Bullish | Relevance: 91%
-  This article evaluates three healthcare stocks, recommending McKesson (MCK) due to its strong financials, market scale, and effective share repurchases. Conversely, Omnicell (OMCL) and Labcorp (LH) are identified as less attractive investments due to stagnant sales, declining margins, and increased costs. The analysis provides fundamental reasons for investors to consider buying McKesson while being cautious about Omnicell and Labcorp.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (1 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $98.9B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.1 |
| Current P/E | 20.6 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -8.2% to -5.7% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 8.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-11.15), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.67% (CS: 6) | Weak |
| RSI_14 | 37.5 | Neutral |
| MACD Histogram | -11.15 | Bearish |
| vs SMA20 | 0.941x | Below |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 1.096x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $795.01
- **Stop Loss:** $757.57 (4.7% risk)
- **Target:** $832.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 8
- **Position Value:** $6,360.08
- **Portfolio %:** 6.36%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*